DiscoverEndocrine Feedback LoopEFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes
EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes

EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes

Update: 2023-01-19
Share

Description

Join host Chase Hendrickson, MD, from Vanderbilt University Medical Center as he discusses an article in The Journal of Clinical Endocrinology & Metabolism with Ashok Balasubramanyam, MD, from Baylor College of Medicine and guest expert David Nathan, MD, from Harvard Medical School and Massachusetts General Hospital. The featured article, by Edwards et al, was first published online in October 2022 in JCEM: “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/journals/endocrine-feedback-loop-podcast-series
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes

EFL033 - GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes